Ikoma, Y., Nakamura, N., Kitagawa, J., Hayase, N., Takada, E., Matsumoto, T., . . . Shimizu, M. (2025). Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High‐Dose Cytarabine‐Based Chemotherapy as Second‐Line Treatments for Relapsed or Refractory Diffuse Large B‐Cell Lymphoma. Wiley. https://doi.org/10.1002/hon.70164
Citazione stile Chigago Style (17a edizione)Ikoma, Yoshikazu, et al. Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High‐Dose Cytarabine‐Based Chemotherapy as Second‐Line Treatments for Relapsed or Refractory Diffuse Large B‐Cell Lymphoma. Wiley, 2025. https://doi.org/10.1002/hon.70164.
Citatione MLA (9a ed.)Ikoma, Yoshikazu, et al. Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High‐Dose Cytarabine‐Based Chemotherapy as Second‐Line Treatments for Relapsed or Refractory Diffuse Large B‐Cell Lymphoma. Wiley, 2025. https://doi.org/10.1002/hon.70164.